CORTINOVIS DIEGO LUIGI

Pubblicazioni

  • De Luca, C., Pepe, F., Iaccarino, A., Pisapia, P., Righi, L., Listì, A., et al. (2021). RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer. CANCERS, 13(1), 139. Dettaglio
  • Cortinovis, D., Migliorati, F., & Pagni, F. (2020). ALK determination: Liquid and tissue biopsy. Comparing techniques and effectiveness of alectinib in a controversial clinical case [Determinazione di ALK: Tra biopsia liquida e tissutale. Tecniche a confronto ed efficacia di alectinib in un caso clinico controverso]. RECENTI PROGRESSI IN MEDICINA, 111(7), E17-E20. Dettaglio
  • Bani, M., Rossi, E., Cortinovis, D., Russo, S., Gallina, F., Hillen, M., et al. (2020). Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale. EUROPEAN JOURNAL OF CANCER CARE. Dettaglio
  • Sharma, G., Cortinovis, D., Agustoni, F., Arosio, G., Villa, M., Cordani, N., et al. (2019). A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib. JOURNAL OF THORACIC ONCOLOGY, 14(11), e257-e259. Dettaglio
  • Giordano, F., Vaira, V., Cortinovis, D., Bonomo, S., Goedmakers, J., Brena, F., et al. (2019). p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 38(1). Dettaglio